# A 3-fold Crossover Bioequivalence Study Between Glucobay Orally Disintegrating Tablet (ODT) and Glucobay Standard Tablet

> **NCT01388153** · PHASE1 · COMPLETED · sponsor: **Bayer** · enrollment: 33 (actual)

## Conditions studied

- Diabetes Mellitus, Type 2

## Interventions

- **DRUG:** Acarbose (Glucobay ODT, BAYG5421)
- **DRUG:** Acarbose (Glucobay ODT, BAYG5421)
- **DRUG:** Acarbose (Glucobay, BAYG5421)

## Key facts

- **NCT ID:** NCT01388153
- **Lead sponsor:** Bayer
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2011-06
- **Primary completion:** 2011-07
- **Final completion:** 2011-08
- **Target enrollment:** 33 (ACTUAL)
- **Last updated:** 2013-08-28


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01388153

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01388153, "A 3-fold Crossover Bioequivalence Study Between Glucobay Orally Disintegrating Tablet (ODT) and Glucobay Standard Tablet". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT01388153. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*